Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss is mainly influenced by genetics and DHT sensitivity. Treatments discussed include minoxidil, oral minoxidil, and finasteride.

A dermatologist refused to prescribe finasteride due to concerns about recent research linking it to male breast cancer, suggesting a topical alternative with minoxidil instead. The user is advised to seek a second opinion, as the evidence for such risks is inconclusive and the dermatologist's reasoning seems questionable.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.

The user experienced chest pain and increased heart rate after microneedling while using topical minoxidil for hair loss. They are unsure if minoxidil is effective without microneedling.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

The conversation discusses the high cost of CB-03-01, a topical antiandrogen for hair loss, which is considered safe and remains localized upon application. It questions whether the expense is justified compared to the lower risks it poses relative to finasteride.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.

A healthy scalp barrier is crucial for hair growth, and ceramides may play a key role in maintaining it. The conversation suggests that focusing on scalp health, alongside treatments like Minoxidil, Finasteride, and RU58841, could improve hair follicle health.

The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.

The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.

Microneedling regimens for hair loss, with users discussing needle lengths and frequencies. One user reports noticeable improvement at the crown using 1mm weekly, while another uses Keto shampoo with dermastamping.

A 30-year-old MTF individual shared a 6-month update on hair loss improvement using minoxidil, retinol, and microneedling, along with lowering testosterone to reduce DHT. They reported positive results, feeling happier and more confident.

A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.

A 27-year-old is experiencing hair thinning and receding, currently using finasteride and planning to start minoxidil. They seek advice on hairline treatment options, including styling, PRP, peptides, and micro-needling.

Capronium Chloride and Trichoxidil are suggested as better alternatives to Minoxidil for hair growth without heart side effects. The Japanese Dermatological Association recommends topical Minoxidil over Capronium Chloride.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.